Nuvalent (NUVL) Income from Continuing Operations (2020 - 2026)
Nuvalent (NUVL) reported Income from Continuing Operations of 109279000.0 for Q1 2026, down 29.2% on a YoY basis from 154346436.97 in Q1 2025, and up 7.95% quarter-over-quarter from 118720000.0 in Q4 2025.
Nuvalent (NUVL) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Nuvalent has reported Income from Continuing Operations for 7 years, with the latest figure at 109279000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 29.2% year-over-year to 109279000.0; the trailing twelve-month figure through Mar 2026 stood at 450089000.0 (down 49.6% YoY), and the FY2025 full-year result was 425392000.0, down 63.14% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 109279000.0, up from 118720000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 17549000.0 in Q1 2022, with the low at 122437000.0 in Q3 2025.
- Historically, Income from Continuing Operations has averaged 59029058.82 across 5 years, with a median of 44482000.0 in 2024.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations plunged 184.79% — and 2026, when it decreased 29.2%.
- Nuvalent's Income from Continuing Operations stood at 26117000.0 in 2022, then slumped by 46.62% to 38292000.0 in 2023, then sank by 95.24% to 74763000.0 in 2024, then plunged by 58.8% to 118720000.0 in 2025, then rose by 7.95% to 109279000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 109279000.0 (Q1 2026), 118720000.0 (Q4 2025), and 122437000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -56.48 Mn |
| 10 | Nuvalent | 9.70 Bn | 9.70 Bn | - | -109.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -109.28 Mn |
| Dec 31, 2025 | -118.72 Mn |
| Sep 30, 2025 | -122.44 Mn |
| Jun 30, 2025 | -99.65 Mn |
| Mar 31, 2025 | -84.58 Mn |
| Dec 31, 2024 | -74.76 Mn |
| Sep 30, 2024 | -84.35 Mn |
| Jun 30, 2024 | -57.17 Mn |
| Mar 31, 2024 | -44.48 Mn |
| Dec 31, 2023 | -38.29 Mn |
| Sep 30, 2023 | -33.65 Mn |
| Jun 30, 2023 | -29.09 Mn |
| Mar 31, 2023 | -25.19 Mn |
| Dec 31, 2022 | -26.12 Mn |
| Sep 30, 2022 | -19.72 Mn |
| Jun 30, 2022 | -18.47 Mn |
| Mar 31, 2022 | -17.55 Mn |
| Dec 31, 2021 | -17.38 Mn |
| Sep 30, 2021 | -12.43 Mn |
| Jun 30, 2021 | -9.85 Mn |